Afrik Pharmaceuticals plc, an
indigenous producer of intravenous solutions, has said investors are
rallying resources to ensure the firm takes the lead in the manufacture
of intravenous drugs in the country.
With an installed capacity of
396,000 litres annually, it has proposed a 300 percent increase within
the next 12 months, equivalent to 1.2 million litres of intravenous
products yearly.
Emeka Onyema, chairman, board of
directors, who disclosed this at the extra-ordinary general of the
company in Lagos, said the company was set to achieve this through
increase in its market share, opening a new range of medical products
and aggressive marketing strategy.
Onyema confirmed that drips were one of the most important and basic medical products.
While the demand for made-in
Nigeria infusions currently stands at over 60 million litters per annum
within Nigeria and other African countries, Onyema noted that its
planned to expand its production capacity in a bid to capture market
share in the intravenous market in the country.
A cursory look at Nigeria’s
intravenous infusion market shows that IV infusion therapy is becoming
increasingly important in overall health care treatment regimens as new
developments in antibiotics and other medications used in areas such as
chemotherapy, burn centres, and renal/peritoneal dialysis centres favour
intravenous use and application.
Interestingly, over 8 million
(5%) of Nigeria’s 160 million people, representing those who are in the
hospital, use infusions of varying volumes with the demand for IV
infusion in Nigeria estimated to be huge.
No comments:
Post a Comment